Important Points to Consider Before Investing in VTRS

Shares of Viatris have moved -0.7% today, and are now trading at a price of $9.59. In contrast, the S&P 500 index saw a 1.0% change. Today's trading volume is 4,032,021 compared to the stock's average volume of 8,962,714.

Viatris Inc. operates as a healthcare company worldwide. Based in Canonsburg, United States the company has 38,000 full time employees and a market cap of $11,503,493,120. Viatris currently offers its equity investors a dividend that yields 5.0% per year.

The company is now trading -35.12% away from its average analyst target price of $14.78 per share. The 9 analysts following the stock have set target prices ranging from $10.0 to $35.0, and on average give Viatris a rating of hold.

Over the last 52 weeks, VTRS stock has risen 4.0%, which amounts to a -19.0% difference compared to the S&P 500. The stock's 52 week high is $12.4 whereas its 52 week low is $8.73 per share. Based on Viatris's average net margin growth of 46.3% over the last 3 years, its core business is on track for profitability and its strong stock performance may continue in the long term.

Date Reported Total Revenue ($ k) Net Profit ($ k) Net Margins (%) YoY Growth (%)
2023-02-27 16,262,700 2,078,600 13 285.71
2022-02-28 17,886,300 -1,269,100 -7 -16.67
2021-02-08 11,946,000 -669,900 -6
The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS